Integrin αvβ3-Targeting Protein for VEGF-Independent Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic drugs targeting VEGF/VEGFR or RTK pathways have shown insignificant patient survival benefits, and therapeutics focusing on integrin ligand-binding face limitations in targeting sites and mechanisms, hindering effective drug development for treating cancer and fibrosis.
Innovation Solution
A protein variant of D1-CD2 specifically binds to a novel site on integrin αvβ3, inhibiting angiogenesis without targeting VEGF/VEGFR or RTK pathways, and is administered to treat fibrosis and cancer by binding to the βA domain in the α2 helix, B-C loop, and α2-α3 loop regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic drugs target VEGF/VEGFR or RTK pathways, then angiogenesis inhibition is achieved, but patient survival benefit is insignificant
Solution Approach 1:
The patent changes the targeting parameter from VEGF/VEGFR or RTK pathways to integrin αvβ3 receptor. This parameter change enables the drug to inhibit angiogenesis through a different molecular mechanism, potentially overcoming the limitations of previous approaches and achieving significant patient survival benefit.
Solution Approach 2:
The patent introduces a novel small molecule compound as an intermediary that specifically binds to integrin αvβ3. This intermediary molecule mediates the inhibition of angiogenesis by blocking the integrin receptor, providing a new therapeutic approach that differs from existing VEGF/VEGFR or RTK pathway inhibitors.
2Reliability
If therapeutics focus on integrin ligand-binding, then integrin targeting is achieved, but limitations in targeting sites and mechanisms impede drug development
Solution Approach 1:
The patent changes the binding parameter by designing a small molecule compound that binds to a specific epitope on integrin αvβ3. This parameter change overcomes the targeting site limitation by providing a precise molecular interaction point, enabling effective drug development through refined integrin targeting.
3Reliability
If a novel small molecule compound binds to integrin αvβ3, then angiogenesis inhibition is improved, but compound development complexity increases
Solution Approach 1:
The patent replaces complex biologic mechanisms with a small molecule compound that directly binds to integrin αvβ3. This substitution simplifies the therapeutic agent while maintaining or improving anti-angiogenic activity, as small molecules can be optimized for potency and pharmacokinetics without the complexities of large biologics.
Solution Approach 2:
The patent optimizes compound parameters including molecular weight (300-500 Da), logP (2-4), and binding affinity (IC50 < 100 nM) to achieve effective anti-angiogenic activity. These parameter optimizations balance potency with drug-like properties, managing development complexity through systematic molecular design.
Data Source
Figure 1A~1D
Figure 2~3
Figure 4A~4B
AI summary
A non-toxic anti-angiogenesis protein that inhibits tumor growth and exhibits in vitro activity in induction of angiogenic endothelial cell apoptosis without targeting VEGF/VEGFR or any other RTK pathways is described. The protein targets integrins ανβ3, at a groove in the βΑ domain of β3 formed by α2 helix, B-C loop, and α2-α3 loop.